glp-1 agonists with cardiovascular benefit benefits of glucagon-like peptide-1 receptor In patients with #obesity, incretin-based
Description
J., Lewis, G., Jones, P
American Gastroenterological Association

Peptide Sciences has the longest track record but has received mixed ratings in some independent analyses for retatrutide specifically
Pharmacokinetic and Dose-finding Studies on Efpeglenatide in Patients with Type 2 Diabetes

Currently, NICE guidance (NG71) for Parkinson's disease does not recommend GLP-1 receptor agonists for treating this condition

In weight loss clinical trials, semaglutide helped people lose about 15 percent of their body weight on average significantly more than the currently available obesity drugs and more than enough to improve health outcomes
